Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Vera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Vera Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:33 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212143
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $86,011 | $41,278 |
| General and administrative | 39,121 | 15,916 |
| Total operating expenses | 125,132 | 57,194 |
| Loss from operations | (125,132) | (57,194) |
| Other income (expense): | ||
| Interest income | 6,355 | 6,906 |
| Interest expense | (1,823) | (1,792) |
Item 1. Financial Statements
FAQ
- What is Vera Therapeutics's R&D?
- Vera Therapeutics (VERA) reported R&D of $86.01M in Q1 2026.
- How has Vera Therapeutics's R&D changed year-over-year?
- Vera Therapeutics's R&D increased by 108.4% year-over-year, from $41.28M to $86.01M.
- What is the long-term trend for Vera Therapeutics's R&D?
- Over 4 years (2021 to 2025), Vera Therapeutics's R&D has grown at a 75.9% compound annual growth rate (CAGR), from $22.48M to $215.26M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Vera Therapeutics's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude